Search
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.
Etoperidone
go.drugbank.com/drugs/DB09194ApprovedWithdrawnEtoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.
Exagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigational[L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … [L49246] In January 2024, exagamglogene autotemcel received an additional FDA approval for the treatment of transfusion-dependent β-thalassemia.
Trimetrexate
go.drugbank.com/drugs/DB01157ApprovedIt is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] Avelumab was first approved by the FDA on March 23, 2017. … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigationalEnfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. … The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Profenamine
go.drugbank.com/drugs/DB00392ApprovedIt is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada.[L46812] In the US, the marketing of profenamine has been discontinued.[L46817]
Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamineBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalOn May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].
Synonyms: (+)-(r)-n-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide, N-((8r)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamideNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalIt was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household setting